Search research articles
Contact Us
Filters
Showing results (61-70 of 77) with videos related to
Page
of 8
Sort By:
American Journal of Clinical Oncology
|
September 19, 2023
Secondary Breast Angiosarcoma After a Primary Diagnosis of Breast Cancer: A Retrospective Analysis of the Surveillance, Epidemiology, and End Results (SEER) Database
Bonny Chau, Elizabeth T Loggers, Lee D Cranmer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 29, 2022
A Phase 1/2 Trial Combining Avelumab and Trabectedin for Advanced Liposarcoma and Leiomyosarcoma
Michael J Wagner, Yuzheng Zhang, Lee D Cranmer, et al.
Journal of Palliative Medicine
|
May 7, 2026
Implementation of Structured Oncologist Communication Skills Training within the Improving Goal Concordant Care Initiative: Lessons Learned and Future Progress
Sahana Rajasekhara, Heather N Bitar, Elizabeth T Loggers, et al.
JAMA Network Open
|
April 12, 2024
Incidence and Presenting Characteristics of Angiosarcoma in the US, 2001-2020
Michael J Wagner, Vinod Ravi, Stephanie K Schaub, et al.
Cancer Research Communications
|
September 8, 2025
Preclinical Evaluation of Folate Receptor-α Chimeric Antigen Receptor T Cells Exhibits Highly Efficient Antitumor Activity against Osteosarcoma
Michelle Choe, Danielle Kirkey, Isabel Lira, et al.
JAMA Oncology
|
September 10, 2020
Assessment of Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma: A Phase 1/2 Nonrandomized Clinical Trial
Seth M Pollack, Mary W Redman, Kelsey K Baker, et al.
Cancer Medicine
|
August 11, 2022
A phase II trial of regorafenib in patients with advanced Ewing sarcoma and related tumors of soft tissue and bone: SARC024 trial results
Steven Attia, Vanessa Bolejack, Kristen N Ganjoo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 24, 2019
Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma
Lara E Davis, Vanessa Bolejack, Christopher W Ryan, et al.
The Oncologist
|
July 24, 2020
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment-Refractory Liposarcoma: Results from the SARC024 Study
Richard F Riedel, Karla V Ballman, Yao Lu, et al.
The Lancet. Oncology
|
October 9, 2020
Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study
Mrinal Gounder, Patrick Schöffski, Robin L Jones, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 77) with videos related to
Sort By:
Page
of 8
American Journal of Clinical Oncology
|
September 19, 2023
Secondary Breast Angiosarcoma After a Primary Diagnosis of Breast Cancer: A Retrospective Analysis of the Surveillance, Epidemiology, and End Results (SEER) Database
Bonny Chau, Elizabeth T Loggers, Lee D Cranmer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 29, 2022
A Phase 1/2 Trial Combining Avelumab and Trabectedin for Advanced Liposarcoma and Leiomyosarcoma
Michael J Wagner, Yuzheng Zhang, Lee D Cranmer, et al.
Journal of Palliative Medicine
|
May 7, 2026
Implementation of Structured Oncologist Communication Skills Training within the Improving Goal Concordant Care Initiative: Lessons Learned and Future Progress
Sahana Rajasekhara, Heather N Bitar, Elizabeth T Loggers, et al.
JAMA Network Open
|
April 12, 2024
Incidence and Presenting Characteristics of Angiosarcoma in the US, 2001-2020
Michael J Wagner, Vinod Ravi, Stephanie K Schaub, et al.
Cancer Research Communications
|
September 8, 2025
Preclinical Evaluation of Folate Receptor-α Chimeric Antigen Receptor T Cells Exhibits Highly Efficient Antitumor Activity against Osteosarcoma
Michelle Choe, Danielle Kirkey, Isabel Lira, et al.
JAMA Oncology
|
September 10, 2020
Assessment of Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma: A Phase 1/2 Nonrandomized Clinical Trial
Seth M Pollack, Mary W Redman, Kelsey K Baker, et al.
Cancer Medicine
|
August 11, 2022
A phase II trial of regorafenib in patients with advanced Ewing sarcoma and related tumors of soft tissue and bone: SARC024 trial results
Steven Attia, Vanessa Bolejack, Kristen N Ganjoo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 24, 2019
Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma
Lara E Davis, Vanessa Bolejack, Christopher W Ryan, et al.
The Oncologist
|
July 24, 2020
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment-Refractory Liposarcoma: Results from the SARC024 Study
Richard F Riedel, Karla V Ballman, Yao Lu, et al.
The Lancet. Oncology
|
October 9, 2020
Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study
Mrinal Gounder, Patrick Schöffski, Robin L Jones, et al.
Page
of 8